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BY4741 haploid wild type yeast was mutagenized with EMS 
,,. ,. 
Plated onto YPD media containing: 
Nystatin - selects for ergosterol biosynthesis mutants 
Squalestatin - inhibits squalene synthase, mimic of erg9 mutation 
Cholesterol - restores growth, supplants ergosterol 
Picked 200 colonies 
"I ,. 
Replica plated all 200 colonies onto YPD+squalestatin and 
YPD+squalestatin+ergostero 1 plates 
Screened for colonies that only grew in the presence of ergosterol 
134 colonies grew on both plates, only 66 demonstrated ergosterol dependent 
growth 
,,. ,. 
Grew the 66 positive colonies in liquid YPD+squalestatin+ergosteroi media and 
screened for fameso 1 accumulation 
20 colonies did not accumulate FOH 
46 colonies accumulated 1-60 mg FOH/L 
9 colonies accumulated more than 50 mg FOH/L 
,,. ,. 
Introduce ERG9 Knockout mutations in the 8 of the 9 selected lines, 
First, verify for no growth without ergosterol addition to the media, 
follow-up with PCR confirmation of erg9 KO, then screened for FOH 
accumulation by 8 independent colonies from each line. 
Eleven of 64 independent lines accumulated more than 70 mg/L FOH in small 
scale test tube culture. 
Figure 15 
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METHOD AND SYSTEM FOR TERPENE 
PRODUCTION PLATFORMS IN YEAST 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of provisional patent 
application No. 61/730,412, filed Nov. 27, 2012, herein 
incorporated by reference. 
FIELD OF THE INVENTION 
The presently-disclosed subject matter relates to methods 
for producing or generating modified yeast, and the resulting 
yeast, and in particular yeast that can be used for various 
aspects of terpene production. For example, the subject 
matter relates to methods and systems for building terpene 
production platforms in yeast which have various introduced 
mutations. These platforms or cell lines can be further 
modified, e.g. genetically engineered to produce specific 
enzymes and/or terpenes. 
BACKGROUND OF THE INVENTION 
2 
Monoterpenes are well known as the volatile essence of 
flowers and plants and such mixtures can account for up to 
5% of plant dry weight (Buchanan et al., 2002). Menthol and 
camphor are common monoterpenes found in diverse plant 
5 families and whose structural complexity in terms of stereo-
and regio-chemistry are emphasized in FIG. 2. Besides 
providing pleasing fragrances, monoterpenes have been 
shown to function as signal molecules in defense mecha-
nisms against pathogens (Hick et al., 1999). Hence, 
10 monoterpenes have the commercial value as flavors, fra-
grances, essential oils, and as anticancer and antimicrobial 
drugs (Burke et al., 1997). Sesquiterpenes (C15) are also 
found in essential oils, and many sesquiterpenes possess 
antibiotic activities, prompting suggestions that they are 
15 produced by plants as a defense mechanism. Diterpenes 
(C20) include gibberellins (plant hormones), vitamin A, as 
well as pharmaceutical important metabolites such as taxol, 
an exceptional anticancer regent (Barkovich & Liao, 2001). 
Triterpenes (C30) include the brassinosteroids, phytosterols 
20 important for lipid membrane composition, and components 
of surface waxes, such as oleanolic aid of grapes. Squalene, 
the major content of shark liver oil, is a linear triterpene and 
common ingredient in cosmetic products (Buchanan et al., 
2002), has special utility as a lubricant for high performance 
25 machinery, and is a common adjuvant in many pharmaceu-
tical formulations (Bhilwade et al., 2010, Huang et al., 2009, 
Reddy & Couvreur, 2009). Tetraterpenes (C40) include 
carotenoid accessory pigments, like lycopene, the monocy-
clic gamma-carotene, and the bicyclic alpha- and beta-
Plants, microorganisms and animals produce a large vari-
ety of organic chemical compounds, some of which are used 
universally for growth and metabolism and others seem to 
play specialized roles in the life cycle of the organism 
(Maimone & Baran, 2007). As such, two large classes of 
natural products are widely recognized. Primary metabolites 
are those essential for live in all eukaryotic organisms, while 
specialized metabolites appear to give species specific 
advantages for occupying distinct environmental niches. 
The distinctive role specialized metabolites play in an organ-
isms natural history, for example how these metabolites 35 
provide protection against microbial challenge, have also 
not escape attention for their possible utility in a wide range 
30 carotenes, which perform essential for the light reactions of 
photosynthesis. Longer chain terpenes, so-called polyter-
penes, contain more than 8 isoprene units and include 
examples like ubiquinone and rubber (Buchanan et al., 
2002). 
There are two pathways for terpene biosynthesis in plant 
cells. One is the mevalonate pathway pathway (MVA) which 
is well established and discovered in the 1960s (Bouvier et 
al., 2005). The other is the mevalonate independent pathway, 
or more properly referred to as the methylerythritol-phos-
of applications. For example, many of the currently used 
drugs are derived or inspired from plant-derived specialized 
chemicals and are commonly referred to as Natural Products 
(Buchanan et al., 2002). Capturing the chemical and struc-
tural diversity of Natural Products has recently been iden-
tified as a major objective within the scientific community in 
large part because of the wide array of applications Natural 
Products can have and the resulting economical implica-
tions. 
Terpenes and terpenoids are a large and diverse family of 
Natural Products with more than 55,000 having been iden-
tified (Maimone & Baran, 2007). However, based on the 
biosynthetic mechanisms responsible for terpenes, chemists 
have predicted that only a small fraction of all the possible 
terpene compounds have been discovered (Bouvier et al., 
2005). Terpenes are derived from the five carbon isoprene 
unit with different combinations of the isoprene units gen-
erating different classes of the terpene products. The clas-
sification and biosynthesis of terpenoids are based on the 
number of five-carbon units they contain as illustrated in 
FIG. 1. Monoterpenes (consisting of 10 carbons), sesquit-
erpenes (15 carbon derivatives), and diterpenes (20 carbon 
derivatives), arise from the corresponding intermediates 
geranyl diphosphate (GPP), farnesyl diphosphate (FPP), and 
geranylgeranyl diphosphate (GGPP). These intermediates in 
turn arise by the sequential head to tail condensation of CS 
units. Higher order terpenes like triterpene (30 carbons) are 
formed from two famesyl units condensed head-to-head. 
Likewise, tetraterpenes ( 40 carbons) are formed from two 
geranylgeranyl units condensed head-to-head. 
40 phate pathway (MEP), which was more recently discovered 
(Bouvier et al., 2005). The MEP pathway was first discov-
ered in prokaryote cells, and then confirmed to exist in plant 
cells (Barkovich & Liao, 2001). Interestingly, plants utilize 
these two pathways to meet different terpene biosynthetic 
45 needs. Sesquiterpenes, sterols, triterpenes and oligoterpenes 
(side chain of dolichols) are synthesized in the cytosol via 
the MVA pathway, while monoterpenes, diterpenes, terater-
penes, and polyterpenoids are synthesized in chloroplasts 
via the MEP pathway using pyruvate and glyceraldehydes-
50 3-phosphate as the primary precursors (FIG. 2). 
The principal product of the mevalonate pathway is 
sterols, for example cholesterol in animal cells, stigmasterol 
and campesterol in plant cells, and ergosterol in fungi, which 
all play essential roles in establishing the structural integrity 
55 of membranes, establishing permeability and fluidity, and 
also serving as signal compounds in cellular communication 
(Buchanan et al., 2002). In Saccharomyces cerevisiae, only 
the mevalonate pathway is known to operate and no com-
ponents of the MEP pathway have been found (Maury et al., 
60 2005). FIG. 3 shows the intermediates and the related genes 
involved in the yeast mevalonate pathway (Maury et al., 
2005). Two molecules of acetyl-CoA are condensed by 
acetoacetyl-CoA thiolase, which is encoded by ERGl0, to 
synthesize acetoacetyl-CoA. A second condensation reac-
65 tion between acetoacetyl-CoA and acetyl-CoA is then cata-
lyzed by HMG-CoA synthase encoded by ERG13 to yield 
3-hydroxy-3methyglutaryl-CoA (HMG-CoA). 
US 10,738,328 Bl 
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TABLE 1 
Biological activities and commercial applications of typical terpenoids 
Commercial 
Class Biologic activities applications Examples 
Monoterpenoids Signal molecules and Flavors, fragrances, Limonene, menthol, 
used as defense cleaning products, camphor, linalool 




Sesquiterpenoids Antibiotic, antiturnor, Flavors, fragrances, Nootkatone, 
antiviral, immuno- pharmaceuticals artemisinin, patchoulol, 
suppressive, and ( antibacterial, nerolidol, famesol, 
hormonal activities, antifungal), capsidol, famesene, 
defensive agents or insecticides, biofuels bisabolene 
pheromones 
Diterpenoids Hormonal activities, Anticancer agents, Gibherellins, phytol, 
growth regulator, feedstock for taxol, kaurene, 
anti tumor, industrial chemical abietadiene, kaurenoic 
antimicrobial and applications acid, abietic acid 
anti-inflammatory 
properties 
Triterpenoids Membrane Biologic markers, Sterols, hopanoids, 
component, steroid biofuel, skin squalene, 




Tetraterpenoids Antioxidants, Food additives, Lycopene, beta-





HMG-CoA is reduced by HMG-CoA reductase to yield 
mevalonate. This reaction is catalyzed by HMG-CoA reduc-
tase, which is encoded by 2 separate loci in yeast. Both loci 
appear to compensate for a knockout loss of the other gene. 
The CS position of mevalonate is phosphorylated by 
mevalonate kinase, encoded by ERG12. Then a second 
kinase, phosphomevalonate kinase, encoded by ERGS, cata-
lyzes the successive phosphorylation to yield diphosphom-
evalonate. In the next step the diphosphomevalonate is 
converted into IPP (isopentenyl diphosphate) by mevalonate 
diphosphate decarboxylase, encoded by ERG19. IPP 
isomerase, encoded by IDil converts IPP into DMAPP 
(dimethylallyl diphosphate). The condensation of the CS 
building blocks ofIPP and DMAPP into FPP is catalyzed by 
FPP synthase, which is encoded by ERG20. FPP can then be 
used as substrate for stern! and other isoprenoid biosynthetic 
needs. 
Recent studies have discovered that FPP is also available 
in yeast mitochondria, as evidenced by increasing novel 
sesquiterpene production three-times by targeting a sesqui-
terpene synthase to the mitochondria compartment com-
pared with targeting this same enzyme to the cytosol (Farhi 
et al., 2011 ). The origin of FPP in mitochondria could be the 
IPP and DMAPP arising in cytosol being imported and 
converted in the mitochondria to FPP. Alternatively, a hypo-
thetical leucine metabolism model for the formation of 
terpene in S. cerevisiae is also a possibility. The leucine 
catabolism pathway (MCC pathway) is known to occur in 
the mitochondria of other eukaryotic mammal and plant 
cells (Anderson et al., 1998), in mitochondria leucine 
metabolite to form 3-Hydroxy-3-methylglutaryl-CoA, 
which can be catalyzed by HMGR to produce mevalonic 
acid, and then produce IPP and DMAPP through MVA 
pathway as shown in FIG. 4 (Carrau et al., 2005). Interest-
ingly, a yeast line engineered with a chimeric diterpene 
synthase targeted to the cytoplasm along with prenyltrans-
35 ferases streamlined for GGPP biosynthesis, yielded 2-3 
times more diterpene when the expression vector also pro-
vided a leu2 auxotrophic selection marker gene. The inter-
pretation provided by the authors was that the extra leucine 
40 
produced by the auxotrophic selection marker gene provided 
another source for IPP via the leucine catabolic pathway 
(FIG. 4). (Zhou et al., 2012). 
Prenyltransferases generate allylic diphosphate esters 
GPP, FPP, and GGPP. These compounds can undergo a 
45 variety of reactions, which include cyclization reactions 
catalyzed by terpene synthases, yielding diverse terpenes 
based on regio- and stereo-chemical constraints built into the 
reactions. Prenyltransferases and terpene syntahases utilize 
electrophilic reaction mechanisms to mediate the catalytic 
50 reactions (Ohnuma et al., 1996) and typically share a con-
served aspartate-rich DDXXD motif thought important for 
the initial substrate binding and metal-dependent ionization 
step leading to the first reaction carbocation intermediates. 
In the prenyltranferase reactions, the allylic diphosphate 
55 ester can be ionized to form a carbocation, then condensed 
with a second IPP in another round of elongation. 
Terpenes are a very large class of structurally diverse 
compounds made by organisms in all kingdoms of life. The 
terpenes from plants are perhaps the most extensively 
60 described as evident by well over 100,000 different terpenes 
reported in the literature (Buckingham, 2003). Terpenes are 
also widely recognized for their diverse utility and applica-
tions. For example, taxol, a diterpene widely recognized for 
its application as a chemotherapeutic agent, was first iso-
65 lated from the bark and needles of several Taxits plant 
species (Wall and Wani, 1995). Likewise, Artemisinin, a 
sesquiterpene isolated from the plant Artemisia annua, has 
US 10,738,328 Bl 
5 
been developed as a key pharmacological agent for the 
control of malaria (Tu, 2011 ). Patchouli, another sesquiter-
pene, is a popular aromatic found in colognes, perfumes and 
many other household cleaning products (Wu et al., 2006). 
Menthol is a monoterpene obtained from mint family plants 5 
and is a popular ingredient in many foods and consumer 
products (Bedoukian, 1983). Triterpenes such as squalene, 
obtained from various plant sources and the livers of deep 
sea sharks, have utility as a nutraceutical product, is used 
extensively in many types of cosmetics, has special utility as 10 
a lubricant for high performance machinery, and is a com-
mon adjuvant in many pharmaceutical formulations (Huang 
et al., 2009; Reddy and Couvreur, 2009; Bhilwade et al., 
2010). 
Terpenes are, however, generally made by plants and 15 
microbes in small amounts and components of complex 
mixtures that vary with growth and environmental condi-
tions, making it difficult to reproducibly obtain large 
amounts of any one terpene constituent (Wu et al., 2006). 
Chemical synthesis ofterpenes is often costly and inefficient 20 
(Nicolaou et al., 1994). Chemical synthesis also suffers from 
generating enantiomeric mixtures, which adds other com-
plications if one particular stereochemical form of a terpene 
is desired. Given such difficulties, there are many on-going 
efforts to create robust, reliable and efficient biological 25 
systems for the production of distinct classes of terpenes, 
and more so for the generation of stereochemically pure 
forms of terpenes (Martin et al., 2003; Wu et al., 2006; 
Takahashi et al., 2007; Asadollahi et al., 2008; Kirby et al., 
2008; Seki et al., 2008; Keasling, 2009; Asadollahi et al., 30 
2010; Fischer et al., 2011). 
SUMMARY OF THE INVENTION 
6 
cell lines. In one further specific form of the present method, 
the ergosterol dependent growth yeast are subject to an erg9 
knockout mutation by inserting a foreign gene sequence into 
the ergosterol dependent growth yeast at a location of erg9 
to effect gene replacement, thereby generating the erg9 
knockout mutation. In an alternative further method, the 
foreign gene sequence can confer chemical resistance to the 
ergosterol dependent growth/erg9 knockout mutation yeast 
cell line. 
The present invention, in another form thereof, relates to 
a non naturally occurring yeast which has ergosterol depen-
dent growth and is erg9-. 
The present invention, in yet another form thereof relates 
to ergosterol dependent growth/erg9 knockout mutation 
yeast cell lines produced by the aforementioned method. 
The present method and cell lines provide advantages 
over wild type and other prior known modified yeast cell 
lines. For example, the present method and resulting cell 
lines are especially beneficial for use as terpene platforms 
for further modification to specifically produce desired ter-
penes which include monodie and triterpenes. 
The yeast lines generated in accordance with this disclo-
sure have utility for the production of diverse classes of 
terpenes including monoterpenes, sesquiterpenes, diterpenes 
and triterpenes. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shows biosynthesis of terpenes from natural 
sources, which often occurs as diverse mixtures with vary-
ing compositions in limited amounts due to environmental 
influences, in which roduction of single specific terpenes in 
genetically engineered yeast would alleviate such variability 
and yield highly valued, single entity compounds. 
FIG. 2 is schematic outline of two terpene biosynthetic 
pathways that operate in plants (the MVA and MEP path-
ways), their intracellular locations, and examples of the 
chemical compounds derived from each. 
The presently disclosed subject matter relates to methods 35 
for producing modified yeast cell lines to produce "plat-
forms" in yeast and the resulting modified yeast or plat-
forms. The production platforms can be further modified to 
produce specific terpenes such as monoterpenes, diterpenes 
and/or triterpenes. 
FIG. 3 illustrates mevalonate pathway for ergosterol bio-
40 synthesis in yeast (S. cerevisiae ). 
FIG. 4 illustrates an alternative metabolic pathway for 
HMG-CoA formation pathway through leucine catabolism 
pathway. 
FIG. 5 illustrates the metabolic pathway in modified yeast 
45 strains in accordance with the present invention. 
Referring generally to one specific technique for produc-
ing modified yeast cell lines in accordance with the present 
disclosure, a series of steps are used to generate genetically 
modified yeast. The steps include chemical mutagenesis 
followed by growth on a semi-solid medium containing 
nystatin, squalestatin and cholesterol. Individual yeast colo-
nies growing on the semi-solid medium are screened for 
ergosterol dependent growth and then subject to an erg9 
(squalene synthase) knockout mutation. Yeast having the 
erg9 knockout mutation are confirmed via having ergosterol 50 
dependent growth. Accordingly, the present technique com-
bines chemical mutagenesis to generate ergosterol depen-
dent yeast lines followed by generating erg9- knockout 
mutations in the ergosterol dependent yeast lines. One 
unique aspect of this method includes the use of squalestatin 55 
to screen chemically induced mutations in yeast which show 
ergosterol dependent growth. 
The present invention, or one form thereof relates to a 
method for generating terpene producing cell lines. The 
method includes combining yeast with a chemical mutagen- 60 
esis agent to induce mutations in the yeast to generate 
chemically mutated yeast. The chemically mutated yeast are 
selected by growth in the presence of nystatin, squalestatin 
and cholesterol, followed by selecting for ergosterol depen-
dent growth. The ergosterol dependent growth yeast are 65 
subjected to an erg9 knockout mutation to thereby produce 
ergosterol dependent growth/erg9 knockout mutation yeast 
FIG. 6 is a flow diagram showing the biogenesis of 
modified yeast in accordance with one aspect of the present 
invention. 
FIG. 7 is a graph showing metabolism of two strains 
BY4741(A) and ZX178-08(B). 
FIG. 8 illustrates how yeast strains produced in accor-
dance with the present method can be used for producing 
specific chemicals. 
FIG. 9 shows how the yeast lines developed as outlined in 
FIG. 8 in comparison to the starting yeast line 4741 were 
chemically profiled for their terpene biosynthetic capacities. 
FIG. 10 is a chart showing the production of various 
compounds of different strains in accordance with the pres-
ent invention. 
FIG. 11 is a graph showing quantitation of FOH levels in 
yeast lines having an exogenous stern! requirement growth. 
FIG. 12 is a gel confirming erg9 knockout mutation in 
accordance with the present invention. 
FIG. 13 is a chart showing the quantitation ofFOH levels 
in SUE, erg9 mutant lines of yeast demonstrated to have an 
exogenous stern! requirement for growth and resistance to 
hygromycin. 
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FIG. 14 is a flow chart showing constructs used for 
evaluate yeast sesquiterpene productions. 
FIG. 15 is a flow diagram showing the steps in the 
development of yeast. 
8 
line. In phase I, chemical mutagenesis is used to introduce 
SUE mutations, which are identified by selecting for yeast 
cells that do not have a functioning ergosterol biosynthetic 
pathway and can only grow in the presence of exogenous 
DETAILED DESCRIPTION 
The present method and modified yeast will now be 
described with reference to the figures and exemplary 
experiments, examples and methods. The figures, experi-
ments and examples are merely to provide a more thorough 
understanding of the present method and modified yeast. 
However, other methods and generated yeast can be envi-
sioned consistent with the scope and spirit of the present 
disclosure. 
5 cholesterol. The SUE mutation was created by subjecting 
wild type yeast strain BY4741 to EMS mutagenesis (see 
supplemental materials and methods information for specif-
ics) to introduce random mutations in the whole genome, 
followed by selection on plates containing three important 
10 selection agents: nystatin; cholesterol; and squalestatin. 
Nystatin binds to ergosterol in the cell membrane causing 
non-selective membrane permeability and leads to cell death 
(Silva et al., 2006). Nystatin thus selects against cells that 
have ergosterol in their membranes. However, yeast have an 
15 absolute requirement for sterols in order for their mem-
branes to function properly. Hence, by having the mutagen-
ized yeast plated in the presence of cholesterol, which 
nystatin camiot bind to, only yeast that can take up the 
exogenous cholesterol under aerobic conditions and prop-
FIG. 5 illustrates one approach used to generate yeast cell 
lines in accordance with the present disclosure. The 
approach of FIG. 5 outlines a method for generating yeast 
cell lines that provide for robust biosynthesis or precursors 
that can be utilized in the production of many difference 
classes of terpenes. The strategy takes advantage of the 
native mevalonate (MVA) pathway that operates normally in 
yeast for the biosynthesis of ergosterol, the dominant sterol 
found in yeast. Ergosterol is the main product of the yeast 
mevalonate pathway, is an important membrane component, 25 
and is essential for yeast growth. If the ergosterol biosyn-
thetic pathway is blocked or inhibited, yeast die. In fact, this 
20 erly incorporate the cholesterol into their membranes sur-
vive. Squalestatin is a potent inhibitor of squalene synthase 
and eliminates the yeast's ability to synthesize ergosterol 
(Bergstrom et al., 1995), thus assuring that the surviving 
yeast have a dispensable mevalonate pathway. 
In phase II, yeast lines demonstrating an absolute require-
ment for exogenous sterols for growth were chemical pro-
filed by GC-MS (FIG. 11). Aliquots of those yeast lines 
exhibiting normal growth characteristics, having growth 
rates comparable to wild type yeast, were extracted and their 
is the basis for many pharmacological drugs to control 
fungal infections in man (Maertens, 2004) and agricultural 
chemicals to control fungal infection in plants (Casida, 
2009). To further complicate matters, wild type yeast can 
take up exogenously supplied sterol from their environment 
only under anaerobic conditions. 
30 chemical constituents separated by gas chromatography and 
identified by their mass fragmentation patterns. The parental 
line BY4741 does not accumulate detectable amounts of 
FOH under these conditions. Mutant lines accumulating 50 
In order to be able to efficiently channel terpene biosyn-
thetic intermediates from the ergosterol biosynthetic path- 35 
way, a SUE (sterol uptake enhancement) mutation support-
ing the aerobic uptake and utilization of exogenous sterol 
was first created (Bourot and Karst, 1995; Shianna et al., 
2001 ). A SUE mutation is thus a yeast line that can meet all 
its sterol needs by an exogenous source of sterol, and 40 
therefore making the endogenous ergosterol biosynthetic 
pathway dispensable. The SUE mutation was then comple-
mented by the introduction of a knockout mutation in the 
ERG9 gene (squalene synthase) (Zhang et al., 1993), result-
ing in a yeast line where the MVA pathway was still 45 
operational up to the biosynthesis of FPP and hence, inter-
mediates in the pathway (DMAPP, IPP and FPP) could be 
diverted to the biosynthesis of other non-essential terpene 
components. In order to follow and select for the desired 
mutant lines, the yeast lines could be monitored for farnesol 50 
(FOH) accumulation, the dephosphorylated form offarnesyl 
diphosphate. If the MV A pathway in the yeast line continued 
to operate as proposed, then one would expect carbon flux 
to FPP to continue. But, because the downstream utilization 
of FPP by squalene synthase was abolished, then the accu- 55 
mulating FPP would be subject to the endogenous phos-
phatase activity for its conversion to FOH, which could be 
used as an initial screen for monitoring development of the 
mutant yeast line. Further engineering of such a yeast line 
could then take advantage of the FPP, DMAPP and IPPpools 60 
for their diversion to the biosynthesis of monoterpenes (10 
carbon compounds), sesquiterpenes ( 15 carbon compounds), 
diterpenes (20 carbon compounds) and triterpenes (30 car-
bon compounds). 
The following experiments were conducted to develop 65 
yeast with a dispensible mevalonate pathway. FIG. 6 illus-
trates three (3) phases in the development of a desired yeast 
or more mg/ml ofFOH were selected for phase III knockout 
mutagenesis of the squalene synthase gene, ERG9. 
As shown in FIG. 11, quantitation ofFOH levels in yeast 
lines having an exogenous sterol requirement for growth. 
Yeast lines were grown as test tube shake cultures with 3 ml 
of YPD media containing 40 µg/ml of ergosterol and 40 
µg/ml of squalestatin for 6 days prior to sampling the 
cultures. One ml aliquots of cultures were mixed vigorously 
with 1 ml of acetone, then allowed to stand for 15 min. One 
ml of hexane containing a cedrene external standard was 
then added, vortexed, centrifuged in a clinical centrifuge for 
5 min, and the upper hexane phase removed and concen-
trated to 100 plunder a nitrogen stream. One µl aliquots of 
the hexane extracts were then subjected to GC-MS and FOH 
levels quantified relative to the external standard. 
The objective in phase III was to obtain a knockout 
mutation of the ERG 9 (squalene synthase) gene, thus 
assuring the dispensable nature of the endogenous 
mevalonate pathway for ergosterol biosynthesis. Site spe-
cific recombination was afford by appending 5' and 3' 
regions surrounding the native ERG9 gene onto a hygro-
mycin selection marker gene (see supplementary materials 
and methods information), then introducing this linear gene 
construct into selected yeast lines from the phase II screen-
ing under conditions to promote site-specific, double recom-
bination with the native ERR9 gene. The knockout mutants 
were then selected by plating the cells in the presence of 
ergosterol and hygromycin. Recombination as depicted in 
FIG. 6 should result in the coding region of the ERG9 gene 
being displaced/substituted by the hygromycin resistance 
marker gene. Confirmation of such a substitution event was 
obtained by screening the genomic DNA of the selected 
yeast colonies for the hygromycin marker gene in proximity 
to genomic DNA sequences normally found 3' to the ERG9 
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coding region. Using genomic DNA isolated from hygro-
mycin resistant colonies as template with a hygromycin 
specific primer (HphF) and a primer specific to a genomic 
DNA sequence found 3' to the ERG9 gene (ERG9 450DwR), 
10 
lar manipulations were from Stratagene (San Diego, Calif.), 
Takara (Shiga, Japan), Invitrogen (San Diego, Calif.), and 
New England Biolab (Ipswich, Mass.). 
a PCR amplification product of approximately 1,538 bp 5 
would be expected and is evident in the colonies so tested in 
FIG. 12. 
Bacteria and yeast were grown using standard culture 
practices. YPD media for growing yeast without selection 
consisted of 1 % Bactoyeast extract, 2% Bacto-peptone, and 
2% glucose ( or 0.5% glucose for select experiments). YPDE 
media was YPD media supplemented with ergosterol ( 40 
mg/L) for ergosterol dependent lines. YPDNCS media for 
In FIG. 12, PCR confirmation for the ERG9 knockout 
mutation include DNA isolated from four independent colo-
nies selected for substitution of the hygromycin resistance 
gene for the ERG9 gene, used as PCR template with a 
hygromycin specific primer and a specific primer for the 
genomic DNA surrounding the ERG9 locust. If the HphF 
gene did insert and replace the ERG9 gene, the expected 
amplification product would be 1,538 bp. Independent colo-
nies from each of the erg9 knockout lines were then re-
evaluated for their growth in liquid media and the dispens-
able nature of their mevalonate pathway checked by their 
accumulation of FOH (FIG. 13). 
As shown in FIG. 13, quantitation ofFOH levels in SUE, 
erg9 mutant lines of yeast demonstrated to have an exog-
enous stern! requirement for growth and resistance to hygro-
mycin. Cultures were grown in 3 ml test tube cultures of 
SCE media supplemented with histidine, leucine, uracil, 
tryptophan and methionine for 6 days before extracting and 
quantifying their FOH levels by GC-MS as described in 
FIG. 11. 
Qualification of a New Mutant Yeast Strain for its Utility to 
Produce a Desired Terpene Compound. 
Nine of the yeast lines harboring a SUE mutation and 
having the native ERG9 gene deleted were evaluated indi-
rectly for the available of terpene biosynthetic intermediates, 
and specifically FPP, to support sesquiterpene biosynthesis 
in comparison to the parental strain BY4741 (FIG. 7). 
Hyoscyamus prenmaspirodiene synthase (HPS), a catalyti-
cally active sesquiterpene synthase first isolated from 
Hyoscyamus muticus, was chosen for this evaluation 
because HPS has been characterized for its expression in 
bacteria (Mathis et al., 1997) and in yeast (Takahashi et al., 
2007). An appropriate HPS gene expression vector was 
engineered into the indicated yeast lines and the subsequent 
transformants screened for premnaspirodiene accumulation 
when the yeast were grown as 30 ml shake flask cultures 
with SCE media containing leucine, tryptophan, uracil, and 
methionine for 12 days at 23° C. Yeast line ZXl 78-08 
accumulated the highest level of premnaspirodiene, up to 
114±26 mg/L, with FOH levels of 23.6±14.5 mg/L. In 
comparison, the parental line BY 4 7 41 accumulated 10 times 
less prenmaspirodiene, 10.94±3.12 mg/L, with no famesol 
accumulation detected. 
FIG. 9 shows a comparison of terpene accumulation 
levels in yeast lines (ZX series) developed as terpene 
production platforms. Each of the ZX cell lines as well as the 
wild type parental line (BY4741) were independently trans-
formed with an expression vector harboring the Hyoscyamus 
prenmaspirodiene synthase gene. The yeast lines were then 
grown for 12 days prior to chemically profiling them for 
their cell constituents by GC-MS and quantifying the levels 
of premnaspirodiene and famesol found in each. 
The following experiments methods and procedures pro-
vide additional background with regard to the method for 
producing terpene platforms in yeast and the resulting yeast 
produced. 
Chemical and Media Preparations 
All chemical reagents were obtained from Sigma-Aldrich 
(St. Louis, Mo.), BD Bioscience (Franklin Lakes, N.J.), or 
Fisher Scientific (Chicago, Ill.), while reagents for molecu-
10 the SUE mutation screening was YPD media supplement 
with 40 mg/L Nystatin, 40 mg/L cholesterol and 40 mg/L 
squalestatin. YPDSE media was YPD media supplement 
with 40 mg/L squalestatin and 40 mg/L ergosterol. Minimal 
media, SCE (pH 5.3), contained 0.67% Bacto-yeast nitrogen 
15 base (without amino acids), 2% dextrose, 0.6% succinic 
acid, 0.14% Sigma yeast dropout solution (-his,-leu,-ura,-
trp ), uracil (300 mg/L), L-tryptophan (150 mg/L), L-histi-
dine (250 mg/L), L-methionine (200 mg/L), L-leucine (1 
g/L) and 40 mg/L ergosterol. Cholesterol and ergostrol 
20 stocks were 10 mg/mL in 50% Triton X-100, 50% ethanol 
and kept at -20° C. Selection media was prepared similarly 
except without supplementing the media with the indicated 
reagent based on the yeast auxotrophic makers. All solid 
media plates were prepared with 2% Bacto-Agar. 
25 Ethyl Methane-Sulfonate (EMS) Mutagenesis 
Strain BY 4 7 41 (MATa;his3Al ;leu2A0;metl 5A0;ura3A0) 
(Janke et al., 2004) was used as the parental yeast line. 
BY4741 cells were incubated overnight at 30° C. in 5 ml 
YPD medium with shaking at 200 rpm, and used to establish 
30 a 200 ml YPD shake flask culture. When the yeast culture 
OD600 reached approximately 1.0, the cells were spun 
down by centrifugation (10 min at 4,000xg), and washed 
twice with 20 ml 0.lM sodium phosphate buffer, pH7.0. 
Cells were concentrated by centrifugation again, re-sus-
35 pended in 1 ml 0. lM sodium phosphate buffer, transferred to 
a 14 ml FALCON culture tubes, treated with 300 pi EMS 
(1.2 g/ml, Sigma), followed by incubation at 30° C. for 1 
hour with shaking. To stop the mutagenesis, 8 ml of sterile 
5% sodium thiosulfate (Fisher) were added to yeast cells by 
40 inactive EMS. Cells were pelleted, washed with 8 ml sterile 
water, concentrated by centrifugation, re-suspended in 1 ml 
sterile water and 100 pl aliquots plated onto YPD-NCS agar 
plate (YPD plus 50 mg/L cholesterol, 50 mg/L nystatin, 50 
mg/L squalesatin, 2% Bacto-agar). In some experiments, the 
45 washed cells were resuspend in 1 ml YPDE liquid media for 
recovery overnight before plating on YPD-NCS agar 
medium. The cultures were incubated for up to 2 weeks at 
30° C. until distinct colonies became visible. 
50 
Yeast Transformation and Culture Performance 
Yeast strains were transformed with the respective vector 
constructs using the FROZEN-EZ Yeast Transformation II 
Kit (Zymo Research, Orange, Calif.) according to the manu-
facturer's recommendations. About 1 pg of plasmid or about 
5 pg of linearized DNA was used per transformation and 
55 followed by selection on agar plates of SCE medium lacking 
specified amino acids for the auxotrophic markers or YPDE 
containing 300 mg/L hygromycin B for screening for erg9 
knockout at 30° C. Variable numbers of independent colo-
nies were subsequently picked and used to start 3 ml cultures 
60 in minimal media to characterize their terpene production 
capacities. Aliquots of these cultures were analyzed for 
terpene production after 6 days of incubation at 30° C. with 
shaking by GC-MS. Cultures exhibiting the highest terpene 
production levels were chosen for further studies and 
65 archived as glycerol stocks at -80° C. Selected lines were 
characterized for cell growth and terpene production using 
30 mL shake flask cultures. Starter cultures grown to satu-
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ration in minimal media were inoculated into 30 ml SCE 
media and 1 mL aliquots withdrawn at every other day 
intervals for 10-15 days. Cell growth was monitored as the 
change in optical density at 600 nm every two days, using 
appropriate dilutions for cultures at later stages of growth. 
Terpene production was determined by GC-MS similar to 
the initial screening method. 
GC-MS Detection and Quantification of Terpenes 
To determine terpene accumulation levels, aliquots of 
cultures grown for 6 to 12 days were extracted with hexane 
and aliquots evaluated by GC-MS. In general, to 1 volume 
of culture, 1 volume of acetone was added and mixed 
vigorously for 3 to 5 min to lyre the cells. The sample was 
then allowed to incubate at room temperature for 10 min 
before adding 1 volume of hexane containing a known 
amount of cedrene external standard. The mixture was again 
mixed vigorously, then centrifuged in a clinical centrifuge 
for 5 min at maximum speed. The upper organic layer was 
collected and when necessary, concentrated under a N2 
stream to ½o the original volume. An aliquot of the organic 
phase (1 µ!) was then analyzed by GC-MS with a Varian 
CP-3800 GC coupled to a Varian Saturn 2200 MS/MS 
(Varian Medical Systems) using a Supelco SLB-5 ms fused 
silica capillary column (30 mx0.25 mmx0.25 µm film thick-
ness, Supelco). The initial oven temperature was set at 70° 
C. for 1 min, ramped to 200° C. at 8° C./min, and then 
ramped to 300° C. at 20° C./min and held for 5 min more. 
Farnesol and prenmaspirodiene levels were calculated rela-
tive to the cedrene external standard. 
Construction of the Squalene Synthase (ERG9) Knockout 
Mutation 
The primers ERG9PS1 and ERG-250downS2 were used 
to amplify the hygromycin resistance gene, hphNTl, from 
the PFA6-hph-NT1 vector (Janke et al., 2004), and at the 
same time add DNA sequences homologous to regions 
surrounding the ERG9 gene in the yeast genome. These 
primers are flanked by 42 nucleotide sequences (underlined) 
homologous to DNA sequences found 250 base pairs 5' 
(upstream) and 3' ( downstream), respectively, of the ERG9 
gene found in the yeast genome. The purified PCR fragment 
was transformed into various yeast lines identified for their 
ability to accumulate farnesol (FIG. 11) and grown in 2 ml 
12 
ofYPDE media for an additional 6 hours before being plated 
on YPDE hygromycin (300 mg/L) agar plates at 28° C. 
Independent single colonies were picked for ergosterol 
dependent test, PCR confirmation of recombination with 
5 hphF and ERG9 450DWR primer, as well as farnesol 
production analysis. The recombination sequence was fur-
ther confirmed by DNA sequencing of a corresponding PCR 
amplification product. 
Expression of the HPS Gene in Yeast 
10 
The yeast GPD promoter (Pgpd) was amplified from the 
PYM-N14 plasmid described by Janke et al. (2004) using 
the primers GPD-BamHIF and GPD-NotIR primers and 
inserted into the pESC-His vector digested with BamHl and 
Not! to replace the original GALl/10 promoters. The result-
15 ing plasmid was named pESC-His-gpd. The HPS gene was 
cloned into Not! and Spel sites of pESC-His-gpd to obtain 
the yeast expression vector pESC-His-gpd-HPS as previ-
ously by Takahashi et al. (2007). Yeast lines transformed 
with this construct were then evaluated for their production 
20 
of the sesquiterpene prenmaspirodiene as a measure of the 
available of intermediates of the mevalonate biosynthetic 
pathway for the biosynthesis of new terpenes. 
Referring to FIG. 14, a yeast expression vector was 
designed for a strong, consecutive expression of the sesqui-
25 terpene synthase HPS gene directed by the gpd promoter 
(Pgpd) and termination provided by the ADH terminator 
sequence (ADHterm). 
In FIG. 15, steps are shown for the development of yeast 
having a desirable mevalonate biosynthetic pathway and 
30 
number of colonies screened at each stage. 
FIG. 8 shows FOH accumulation in a yeast line (178-08) 
selected for a dispensable mevalonate biosynthetic pathway 
in comparison to that accumulating in the parental line 
(BY4741) used to generate the new mutant yeast lines. 
35 
GC-MS chromatograph of hexane extracts were prepared 
from the wild type and engineered yeast lines. The top of 
FIG. 8, for (A) BY4741, shows no farnesol accumulated in 
parental yeast. In the bottom part of FIG. 8, (B) ZXl 78-08, 
over 100 mg ofFOH/L accumulated in the newly developed 
40 
yeast line, as quantified on the basis of a cedrene external 
standard. 
The following table shows primers used in various 
molecular manipulations described in the present disclosure. 
Sequence 
Primer Name Primer sequence Identifier 
ERG9p Sl GTACATTTCATAGCCCATCTTCAACAACAATACCGACTTA SEQ ID 
NO: 1 
CCCGTACGCTGCAGGTCGAC SEQ ID 
NO: 2 
ERG9 CAGATTGACGGAGAGAGGGCCACATTGTTTGTCGGCAA SEQ ID 
250dw52 NO: 3 
TAAATCGATGAATTCGAGCTCG SEQ ID 
N0:4 
Hph F ATGGGTAAAAAGCCTGAACTCA SEQ ID 
NO: 5 
Hph R TTATTCCTTTGCCCTCGGACGAG SEQ ID 
NO: 6 
ERG9 AGATGCTAGTCAATGGCAGAAG SEQ ID 
450cl Wr NO: 7 
ERG9p300upF TGCTTACACAGAGTGAACCTGC SEQ ID 
NO: 8 
ERG9 300R CTCGTGGAAGTGACGCAAC SEQ ID 
NO: 9 
HPS Natl F gggGCGGCCGCaAAAACA atggccccagctatagtgatgag SEQ ID 
NO: 10 
HPS SpeIR gACTAGT tcaaatatcaatagaatccacc SEQ ID 
N0:11 
pGPD-BamHIF SegGGATCCagmatcattatcaatactcgcc SEQ ID 
NO: 12 
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-continued 
Primer Name Primer sequence 
pGPD-Not!R gggGCGGCCGCgagctcagmatcattatc 
It will be understood that various details of the presently 
10 
disclosed subject matter can be changed without departing 
from the scope of the subject matter disclosed herein. 
Furthermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose of limitation. 
15 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 13 
<210> SEQ ID NO 1 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer sequence 
<400> SEQUENCE, 1 
gtacatttca tagcccatct tcaacaacaa taccgactta 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer sequence 
<400> SEQUENCE, 2 
cccgtacgct gcaggtcgac 
<210> SEQ ID NO 3 
<211> LENGTH, 38 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer sequence 
<400> SEQUENCE, 3 
cagattgacg gagagagggc cacattgttt gtcggcaa 
<210> SEQ ID NO 4 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer sequence 
<400> SEQUENCE, 4 
taaatcgatg aattcgagct cg 
<210> SEQ ID NO 5 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 5 
atgggtaaaa agcctgaact ca 
<210> SEQ ID NO 6 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 6 
ttattccttt gccctcggac gag 
<210> SEQ ID NO 7 
<211> LENGTH, 22 
<212> TYPE, DNA 










<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 7 
agatgctagt caatggcaga ag 
<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 8 
tgcttacaca gagtgaacct gc 
<210> SEQ ID NO 9 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 9 
ctcgtggaag tgacgcaac 
<210> SEQ ID NO 10 
<211> LENGTH, 41 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 10 
US 10,738,328 Bl 
-continued 
ggggcggccg caaaaacaat ggccccagct atagtgatga g 
<210> SEQ ID NO 11 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 11 
gactagttca aatatcaata gaatccacc 
<210> SEQ ID NO 12 
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 12 
cgggatccag tttatcatta tcaatactcg cc 
<210> SEQ ID NO 13 
<211> LENGTH, 31 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, primer 
<400> SEQUENCE, 13 
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The invention claimed is: 
1. A non-naturally occurring yeast having: 
(a) dispensable mevalonate and ergosterol biosynthetic 
pathways, mutation(s) conferring the ability to use 
exogenous stern! to meet its stern! requirements under 5 
aerobic growth conditions in the presence of nystatin 
and squalestatin but does not require exogenous stern! 
in order to grow in the absence of nystatin and squal-
estatin; 
(b) a wild type squalene synthase gene; 
( c) harboring a mutation in one of the genes associated 
with the enzymes comprising the mevalonate biosyn-
thetic pathway or a mutation in a genetic locus effecting 
production of farnesyl diphosphate or farnesol; and 
( d) accumulating 50 mg/L or greater amounts of farnesol 
when cultured in the presence of nystatin, squalestatin 
and exogenous stern!, 




combining yeast with a chemical mutagenesis agent to 
induce mutations in the yeast to generate chemically 
mutated yeast; 
culturing the chemically mutated yeast in the presence of 
nystatin, squalestatin and cholesterol to produce yeast 25 
which have (i) the dispensable stern! biosynthetic path-
way, (ii) the ability to utilize exogenous sterols to meet 
its aerobic growth needs in the presence of nystatin and 
squalestatin but does not require exogenous stern! in 
order to grow in the absence of nystatin and squalesta- 30 
tin, (iii) the dispensable mevalonate biosynthetic path-
way due to one or more mutations introduced into loci 
of an enzyme comprising the mevalonate biosynthetic 
pathway other than the ERG9 gene locus or a mutation 
in a genetic locus effecting production of farnesyl 35 
diphosphate or farnesol, and (iv) a wild type squalene 
synthase gene; and 
selecting for yeast exhibiting stern! dependent growth and 
farnesyl accumulation in an amount of 50 mg/L or 
greater of farnesol when cultured in the presence of 40 
nystatin and squalestatin to thereby produce the non-
naturally occurring yeast. 
2. The non-naturally occurring yeast of claim 1, wherein 
the yeast harbors a stern! uptake enhancement mutation 
(SUE) or is phenotypically a SUE mutant. 45 
3. The non-naturally occurring yeast of claim 1, wherein 
the yeast is a mutant yeast selected from the group consisting 
of Candida albicans and Saccharomyces cerevisiae. 
4. A method for producing stern! dependent growth yeast 
cell lines generating terpene, the method comprising: 50 
combining yeast with a chemical mutagenesis agent to 
induce mutations in the yeast to generate chemically 
mutated yeast; 
culturing the chemically mutated yeast in the presence of 
nystatin, squalestatin and cholesterol to produce yeast 55 
which have (i) a dispensable stern! biosynthetic path-
way, (ii) an ability to utilize exogenous stern! to meet 
its aerobic growth needs in the presence of nystatin and 
squalestatin but does not require exogenous stern! in 
order to grow in the absence of nystatin and squalesta- 60 
tin, (iii) a dispensable mevalonate biosynthetic pathway 
due to one or more mutations introduced into loci of an 
enzyme comprising the mevalonate biosynthetic path-
way other than the ERG9 gene locus or a mutation in 
a genetic locus effecting production of farnesyl diphos- 65 
phate or farnesol, and (iv) a wild type squalene syn-
thase gene; and 
20 
selecting for yeast exhibiting ergosterol dependent growth 
and farnesyl accumulation in an amount of 50 mg/Lor 
greater of farnesol when cultured in the presence of 
nystatin and squalestatin. 
5. The non-naturally occurring yeast of claim 1, in which 
the yeast are from yeast line ZXl 78. 
6. A stern! dependent growth/ERG9 gene knockout muta-
tion (llerg9) yeast cell lines having: 
(a) dispensable mevalonate and ergosterol biosynthetic 
pathways, mutation(s) conferring the ability to use 
exogenous stern! to meet its stern! requirements under 
aerobic growth conditions in the presence of nystatin 
and squalestatin but will require exogenous stern! in 
order to grow in the absence of nystatin and squalesta-
tin; 
(b) the dispensable mevalonate and ergosterol biosyn-
thetic pathway mutation(s) comprise replacement of 
wild type ERG9 gene with a selectable marker gene; 
( c) harboring a mutation in one of the genes associated 
with the enzymes comprising the mevalonate biosyn-
thetic pathway or a mutation in a genetic locus effecting 
production of farnesol diphosphate or farnesol; and 
( d) accumulating 60 mg/L or greater amounts of farnesol 
when cultured in the presence of exogenous stern! but 
not nystatin and squalestatin, 
the stern! dependent growth/ERG9 gene knockout muta-
tion (llerg9) yeast produced by a method comprising: 
combining yeast with a chemical mutagenesis agent to 
induce mutations in the yeast to generate chemically 
mutated yeast; 
culturing the chemically mutated yeast in the presence of 
nystatin, squalestatin and cholesterol to produce the 
yeast which have (i) the dispensable stern! biosynthetic 
pathway, (ii) the ability to utilize exogenous sterols to 
meet its aerobic growth needs in the presence of 
nystatin and squalestatin but do not require exogenous 
stern! in order to grow in the absence of nystatin and 
squalestatin, (iii) the dispensable mevalonate biosyn-
thetic pathway due to one or more mutations introduced 
into loci of an enzyme comprising the mevalonate 
biosynthetic pathway other than the ERG9 gene locus 
or a mutation in a genetic locus effecting production of 
farnesyl diphosphate or farnesol; 
selecting for yeast with stern! dependent growth and 
farnesol accumulation and for accumulating 50 mg/Lor 
greater amounts of farnesol when cultured in the pres-
ence of nystatin, squalestatin and exogenous stern!; and 
introducing the ERG9 gene mutation by gene replacement 
of wild type ERG9 gene with an antimicrobial resis-
tance gene to produce the yeast that (i) will require 
exogenous stern! in order to grow when cultured in the 
absence of nystatin and squalestatin, and (ii) have 
farnesol accumulation in 60 mg/L or greater when 
cultured in the presence of exogeneous stern!. 
7. The non-naturally occurring yeast of claim 6, wherein 
the yeast harbors a stern! uptake enhancement mutation 
(SUE) or is phenotypically a SUE mutant. 
8. A method for producing stern! dependent growth/ERG9 
gene knockout mutation (llerg9) yeast cell lines, the method 
comprising: 
combining yeast with a chemical mutagenesis agent to 
induce mutations in the yeast to generate chemically 
mutated yeast; 
culturing the chemically mutated yeast in the presence of 
nystatin, squalestatin and cholesterol to produce yeast 
which have (i) a dispensable stern! biosynthetic path-
way, (ii) an ability to utilize exogenous sterols to meet 
US 10,738,328 Bl 
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its aerobic growth needs in the presence of nystatin and 
squalestatin but do not require exogenous sterol in 
order to grow in the absence of nystatin and squalesta-
tin, (iii) a dispensable mevalonate biosynthetic pathway 
due to one or more mutations introduced into loci of an 5 
enzyme comprising the mevalonate biosynthetic path-
way other than the ERG9 gene locus or a mutation in 
a genetic locus effecting production of famesyl diphos-
phate or farnesol; 
selecting for yeast with sterol dependent growth and 
10 
famesol accumulation and for accumulating 50 mg/Lor 
greater amounts of famesol when cultured in the pres-
ence of nystatin, squalestatin and exogenous sterol; and 
introducing an ERG9 gene mutation by gene replacement 
of wild type ERG9 gene with an antimicrobial resis-
tance gene to produce yeast that (i) will require exog- 15 
enous sterol in order to grow when cultured in the 
absence of nystatin and squalestatin, and (ii) have 
famesol accumulation in 60 mg/L or greater when 
cultured in the presence of exogeneous sterol. 
22 
9. The yeast of claim 1, wherein the mutation is in one of 
the genes encoding the enzymes of the mevalonate biosyn-
thetic pathway. 
10. The yeast of claim 6, wherein the mutation is in one 
of the genes encoding the enzymes of the mevalonate 
biosynthetic pathway. 
11. The method of claim 8, further comprises introducing 
an expression vector into the yeast cell line, which vector 
expresses a gene for a terpene synthase. 
12. The method of claim 11, wherein the terpene synthase 
is for sesquiterpene synthase. 
13. The sterol dependent growth yeast cell line of claim 6, 
wherein the method producing the yeast cell line further 
comprises introducing an expression vector into the yeast 
cell line, which vector expresses a gene for terpene synthase. 
14. The sterol dependent growth yeast cell line of claim 
13, wherein the terpene synthase is for sesquiterpene. 
* * * * * 
